Fig. 3: ATM inhibition enhances MHC-I, IRF1 and NLRC5 expression.
From: ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I
A, B FPKM quantification of antigen processing and presentation-related genes (A), IRF1, and NLRC5 (B). C, D Immunoblots showing b2M and GAPDH expression levels in vector control, ATM-KO, and KU60019 (3 μM, 24 h) treated CT26 cells and HCT116 cells. E–J Vector control, ATM-KO, KU60019 (3 μM, 24 h) treated CT26 cells, and HCT116 cells were immunostained with the anti-MHC-I antibody and analyzed with flow cytometry (E–H). qRT-PCR was used to measure the mRNA level of MHC-I, IRF1, and NLRC5 (I and J). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
